Screening for T1D: The Power of Prevention

Early detection of Type 1 Diabetes (T1D) can significantly alter its course, providing opportunities for intervention that could delay or even prevent the onset of the disease. At Touched by Type 1, we believe in the power of prevention and the importance of screening, which is why we want to share vital information about Type 1 Diabetes screening services available to you.

Touched by Type 1 is committed to providing the resources and support needed for early detection and prevention of Type 1 Diabetes. If you are interested in learning more or participating in preventive measures, several organizations offer screening at no cost and access to clinical trials.

For free risk screening, you can visit:

- TrialNet Risk Screening - https://www.trialnet.org/our-research/risk-screening 

- Enable Biosciences T1D Testing = https://type1testing.enablebiosciences.com 

These resources are pivotal in advancing our understanding and prevention of T1D, ensuring that those at risk receive the most informed and effective care possible.

  • Type 1 Diabetes is an autoimmune condition where the immune system mistakenly attacks the insulin-producing cells in the pancreas. Without insulin, the body cannot properly process sugar, leading to elevated blood sugar levels and severe health complications

  • Type 1 Diabetes is an autoimmune condition where the immune system mistakenly attacks the insulin-producing cells in the pancreas. Without insulin, the body cannot properly process sugar, leading to elevated blood sugar levels and severe health complications

  • Autoantibodies are proteins created by the immune system that mistakenly attack the body's own cells. In Type 1 Diabetes, these autoantibodies target and destroy pancreatic cells that produce insulin. They serve as early indicators that someone might develop Type 1 Diabetes.

  • Detecting autoantibodies early provides a significant opportunity for intervention. Individuals who test positive for two or more autoantibodies are at high risk of developing Type 1 Diabetes. Early detection allows healthcare providers to monitor these individuals closely and start preventative treatments to delay or potentially prevent the onset of Diabetes.

  • A major leap in Diabetes prevention is the FDA’s recent approval of Teplizumab (marketed as Tzield). This medication is specifically designed for individuals at high risk of developing Type 1 Diabetes, such as those with multiple positive autoantibodies. Teplizumab works by moderating the immune system’s activity to protect insulin-producing cells, offering new hope for those identified through autoantibody screening.

  • Screening for autoantibodies not only helps in early detection but also empowers individuals and families to take proactive steps in managing their health. For families with a history of Type 1 Diabetes, understanding their risk through these screenings can be especially valuable, providing them with the knowledge and tools to potentially alter their future.

Citations:

- Adapted from content on the Diabetes Research Institute's website: Screening for Type 1 Diabetes: The Power of Prevention - https://diabetesresearch.org/screening-for-t1d-the-power-of-prevention